The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study):a randomized controlled trial
| Autor: | Jesper Ryg, J Gram, Niklas Rye Jørgensen, Stinus Hansen, Tahir Masud, Ditte Beck Jepsen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Osteoporosis Postmenopausal/physiopathology Endocrinology Diabetes and Metabolism Osteoporosis Hip Joint/physiopathology Tomography X-Ray Computed/methods Parathyroid hormone Bone remodeling law.invention chemistry.chemical_compound Absorptiometry Photon 0302 clinical medicine Randomized controlled trial Bone Density law Teriparatide/therapeutic use Teriparatide Osteoporosis Postmenopausal Aged 80 and over Bone mineral teriparatide Lumbar Vertebrae Bone Density Conservation Agents Middle Aged whole-body vibration Combined Modality Therapy Exercise Therapy Bone Remodeling/physiology Medication Adherence/statistics & numerical data Female Hip Joint Original Article Bone Remodeling medicine.drug medicine.medical_specialty Bone Density Conservation Agents/therapeutic use Lumbar Vertebrae/physiopathology Urology 030209 endocrinology & metabolism Vibration Medication Adherence postmenopausal osteoporosis 03 medical and health sciences Animal data medicine Absorptiometry Photon/methods Humans Aged business.industry medicine.disease Exercise Therapy/methods chemistry randomized controlled trial Sclerostin 030101 anatomy & morphology Bone Density/physiology Tomography X-Ray Computed business Biomarkers/blood Biomarkers |
| Zdroj: | Jepsen, D B, Ryg, J, Hansen, S, Jørgensen, N R, Gram, J & Masud, T 2019, ' The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study) : a randomized controlled trial ', Osteoporosis International, vol. 30, no. 9, pp. 1827-1836 . https://doi.org/10.1007/s00198-019-05029-z Osteoporosis International Jepsen, D B, Ryg, J, Hansen, S, Jørgensen, N R, Gram, J & Masud, T 2019, ' The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study) : a randomized controlled trial ', Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 30, no. 9, pp. 1827-1836 . https://doi.org/10.1007/s00198-019-05029-z |
| DOI: | 10.1007/s00198-019-05029-z |
| Popis: | Summary Treatment effects of combining teriparatide and whole-body vibration exercise (WBV) vs teriparatide alone in twelve months were compared using bone mineral density (BMD), bone microarchitecture, and bone turnover markers. We found an increased effect in lumbar spine BMD by adding WBV to teriparatide in postmenopausal osteoporotic women. Introduction The parathyroid hormone (PTH) analogue teriparatide is an effective but expensive anabolic treatment for osteoporosis. Whole-body vibration exercise (WBV) has been found to stimulate muscle and bone strength in some studies. Animal data demonstrate a beneficial effect on bone when combining PTH with mechanical loading. The aim of this study was to investigate if combining WBV exercise and teriparatide treatment gives additional beneficial effects on bone compared to teriparatide alone in postmenopausal women with osteoporosis. Methods The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone. WBV consisted of three sessions a week (12 min, including 1:1 ratio of exercise:rest). Bone mineral density (BMD) and bone microarchitecture, bone turnover markers, and sclerostin measurements were obtained. Data were analyzed using a linear mixed regression model with adjustment for baseline values or robust cluster regression in an intention-to-treat (ITT) analysis. Results Thirty-five women were randomized (17 in teriparatide + WBV group and 18 in teriparatide group). At 12 months, both groups increased significantly in BMD at the lumbar spine. The teriparatide + WBV group increased by (mean ± SD) 8.90% ± 5.47 and the teriparatide group by 6.65% ± 5.51. The adjusted treatment effect of adding WBV to teriparatide was statistically significant at 2.95% [95% CI = 0.14–5.77; P = 0.040]. Markers of bone turnover increased significantly in both groups at three and six months with no significant difference between groups. No other treatment effects were observed in hip BMD, bone microarchitecture parameters, or sclerostin levels in either group. Conclusion Twelve months of WBV and teriparatide had a significant clinically relevant treatment effect in lumbar spine BMD compared to teriparatide alone in postmenopausal osteoporotic women. ClinicalTrials.gov:(NCT02563353). Electronic supplementary material The online version of this article (10.1007/s00198-019-05029-z) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|